10 Best Healthcare Stocks to Buy for the Long Term 

8. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Number of Hedge Fund Holders: 31

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best healthcare stocks to buy for the long term. Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced on May 7 that the company entered into a global collaboration and license agreement with GSK, under which GSK has licensed Halozyme’s ENHANZE® drug delivery technology for the development and potential commercialization of subcutaneous administration of multiple oncology targets. This includes antibody drug conjugates (ADCs), as well as an option for additional future drug targets.

Eric Richards, SVP Head of Medicine Development Leaders Oncology, GSK, said that they “see significant potential for subcutaneous formulations of several promising cancer targets, including ADCs, with ENHANZE and look forward to progressing the first clinical program”.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) further reported that GSK will make an upfront payment to Halozyme and potential future milestone payments, and Halozyme will also be entitled to royalties on net sales of products that incorporate ENHANZE®. In a separate development, H.C. Wainwright lifted the price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $95 from $90 on April 29, maintaining a Buy rating on the shares.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology. They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.